BC Extra | Jul 31, 2019
Clinical News

July 31 Clinical Quick Takes: Novartis' Kisqali shows OS benefit; plus Atlantic and Translate Bio

Kisqali improves survival for postmenopausal breast cancer  Novartis AG (NYSE:NVS; SIX:NOVN) reported interim data showing CDK4/CDK6 inhibitor Kisqali ribociclib plus fulvestrant met the secondary endpoint of significantly improved overall survival in the Phase III MONALEESA-3...
BC Innovations | Jul 19, 2018
Translation in Brief

Inflammatory images

A University of Calgary team has implicated the inflammasome in acute kidney injury induced by contrast imaging agents and identified targets that could help prevent it. In patients with diminished renal function, such as those...
BioCentury | Jul 8, 2017
Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
BC Week In Review | May 12, 2017
Clinical News

Atlantic begins rolling NDA submission for pouchitis candidate alicaforsen

Atlantic Healthcare plc (Saffron Walden, U.K.) began submission of a rolling NDA to FDA for alicaforsen (AP 1007) to treat pouchitis. The antisense inhibitor of intercellular adhesion molecule-1 ( ICAM-1 ; CD54) is in a Phase...
BC Week In Review | May 12, 2017
Clinical News

Atlantic begins rolling NDA submission for pouchitis candidate alicaforsen

Atlantic Healthcare plc (Saffron Walden, U.K.) began submission of a rolling NDA to FDA for alicaforsen (AP 1007) to treat pouchitis. The antisense inhibitor of intercellular adhesion molecule-1 ( ICAM-1 ; CD54) is in a Phase...
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
BC Extra | Mar 22, 2016
Financial News

Atlantic raises $24M venture round

Atlantic Healthcare plc (Cambridge, U.K.) raised $24 million in a venture round from Lorin Johnson and other founders of Salix Pharmaceuticals Inc., Fullbrook Thorpe Investments, LDC and undisclosed existing investors. In 2H17, Atlantic expects results...
BC Week In Review | Feb 15, 2016
Clinical News

Alicaforsen: Phase III started

Atlantic began a double-blind, placebo-controlled, international Phase III trial to evaluate 240 mg topical alicaforsen enema once daily for 6 weeks in 138 patients with active, chronic, antibiotic-refractory pouchitis. Atlantic Healthcare has exclusive, worldwide rights...
BC Innovations | Jul 24, 2014
Cover Story

It is an RNA world

RNA-based molecules have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent. This redefinition has launched RNA as the biotech industry's third drug modality....
BC Week In Review | Apr 15, 2013
Company News

Isis Pharmaceuticals other research news

ISIP researchers reported in the Journal of Biological Chemistry that addition of methoxyethyl to the 2' hydroxyl groups of an antisense oligonucleotide targeting ICAM-1 (cell adhesion molecule) efficiently inhibited ICAM-1 protein production. Treatment of human...
Items per page:
1 - 10 of 101